SER130

DISCOVERY

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

APPROVAL

SER130 is a peptide with anti-inflammatory properties

SER130 is a selective IL-4 modulator, an anti-inflammatory peptide compound with a novel mode of action for the treatment of Obesity. SER130 promotes lipolysis in mature adiposytes while inhibiting adipogenesis. SER130 is consequently expected to selectively reduce fat mass and limit future fat storage.

The GLP-1 therapies are becoming standard of care treatment for obesity. While they reduce overall weight they are not selectively targeting fat, but also may lead to loss of muscle and other vital tissue. SER130 is expected to preserve muscle mass and could therefore become an important treatment option for patients where loss of muscle mass is not desireable.